Last reviewed · How we verify
"Conventional" regimen
This drug works by inhibiting the reuptake of norepinephrine, serotonin, and dopamine.
This drug works by inhibiting the reuptake of norepinephrine, serotonin, and dopamine. Used for Attention deficit hyperactivity disorder (ADHD), Major depressive disorder.
At a glance
| Generic name | "Conventional" regimen |
|---|---|
| Sponsor | Pablo Rodríguez del Rio |
| Drug class | Norepinephrine-dopamine reuptake inhibitor |
| Modality | Biologic |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
By blocking the reuptake of these neurotransmitters, it increases their availability in the synaptic cleft, enhancing their effects on the brain and nervous system. This leads to increased alertness, energy, and mood improvement.
Approved indications
- Attention deficit hyperactivity disorder (ADHD)
- Major depressive disorder
Common side effects
- Increased heart rate
- Insomnia
- Nausea
- Headache
Key clinical trials
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis (NA)
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
- Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (PHASE2, PHASE3)
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- Glycemic Variability Comparing Two vs Five Meals in Type 2 Diabetes (NA)
- Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- "Conventional" regimen CI brief — competitive landscape report
- "Conventional" regimen updates RSS · CI watch RSS
- Pablo Rodríguez del Rio portfolio CI